Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis - A novel approach

Biologicals. 2019 Jul:60:93-94. doi: 10.1016/j.biologicals.2019.06.002. Epub 2019 Jun 13.

Author

Muhammad K Nisar¹

Affiliation

¹ Rheumatology Department, Luton & Dunstable University Hospital NHSFT, Luton, UK. Electronic address: drnisar12@yahoo.co.uk.

PMID: 31204079
DOI: 10.1016/j.biologicals.2019.06.002

No abstract available

Keywords: Ankylosing spondylitis; Combination; Fingolimod; Multiple sclerosis; Secukinumab.

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage*
Fingolimod Hydrochloride / administration & dosage*
Humans
Male
Multiple Sclerosis / complications
Multiple Sclerosis / diagnosis
Multiple Sclerosis / drug therapy*
Spondylitis, Ankylosing / complications
Spondylitis, Ankylosing / diagnosis
Spondylitis, Ankylosing / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
secukinumab
Fingolimod Hydrochloride